Skip to content

Microdosing: all studies

Page 46 of 56: studies 451 to 460 of 555, newest first. Back to the microdosing overview

Research

Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial.

BMC Neuroscience February 5, 2024 Robin J Murphy, Kate Godfrey, Alexander D Shaw et al. 16 citations

Microdosing psychedelics is a phenomenon with claimed cognitive benefits that are relatively untested clinically. Pre-clinically, psychedelics have demonstrated enhancing effects on neuroplasticity, which cannot be measured directly in humans, but may be indexed by non-invasive electroencephalography (EEG) paradigms. This study used a visual long-term potentiation (LTP) EEG paradigm to test the...

A history of the European Medical Society for Psycholytic Therapy (EPT) 1964–1974

Drug Science, Policy and Law 2024 Torsten Passie 4 citations

The emergence of a so-called psychedelic renaissance has been proposed to characterize the revival of research into (psycho-)therapies using psychedelic drugs. In Europe, the most widespread approach employed in the 1960s and 1970s that involved the use of drugs like LSD and psilocybin as an adjunct to psychotherapy was named according to its main theoretical framework, that is, psychoanalysis...

Psychedelics action and schizophrenia.

Pharmacological Reports October 30, 2023 Marzena Maćkowiak 20 citations

Abstract Psychedelics are compounds acting by serotonin 5-hydroxytryptamine (5-HT) 2A receptor activation and induce several behavioral responses. They are of special interest because of their positive effects on neuropsychiatric disorders (depression and posttraumatic stress disorder). However, several findings revealed that some psychedelic actions are similar to symptoms observed in...

DOI: 10.1007/s43440-023-00546-5 (opens in new tab) Full text (opens in new tab) Psychedelics Schizophrenia Consciousness Mental health

Cardiovascular safety of psychedelic medicine: current status and future directions

Pharmacological Reports October 24, 2023 Agnieszka Wsół 56 citations

Abstract Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychiatric diseases was known before their prohibition. An increasing number of recent studies, due to the indisputable resurgence of serotonergic hallucinogens, have shown their efficacy in alleviating depression, anxiety, substance abuse therapies, and...

Tendencias y experiencias del consumo de microdosis de hongos psilocibios en Colombia

Cultura y Droga October 19, 2023 Camila Suárez, Santiago Quintero, Juan Miguel Cardona Gil

El artículo presenta una caracterización preliminar de las prácticas y experiencias de consumo de microdosis de hongos psilocibios en Colombia. Para ello, se realizó un estudio mixto que combinó el análisis estadístico de los datos preliminares de la primera encuesta nacional sobre consumo de microdosis de psicodélicos y el análisis temático de las bitácoras de 19 usuarios que registraron...

Investigación sobre microdosificación con hongos psilocibios: un artículo de reflexión

Cultura y Droga October 19, 2023 Laura Duque

Este artículo de reflexión sobre microdosificación con psilocibina se hizo con base en estudios observacionales, ensayos clínicos, una revisión sistemática y un estudio sociológico. La búsqueda se hizo en Pubmed usando los descriptores “psilocybin” y “microdosing”. Se tomaron artículos desde 2019 hasta enero de 2023, en inglés, enfocados en la microdosificación con psilocibina y principalmente...

Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility study

October 11, 2023 Stefanie Enriquez‐geppert, Jaroslav Krc, Fiachra O'Higgins et al. 1 citation preprint

Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting treatment and training responsiveness. In this pioneering study, we evaluated the feasibility and preliminary efficacy of psilocybin-assisted frontal-midline theta neurofeedback (NF), a neuromodulation technique leveraging neuroplasticity, to improve...

Pharmacists and psychedelic medicine

JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY October 1, 2023 Kelan Thomas

In coming years, pharmacists will begin fielding more questions regarding psychedelic medicine, most notably with the imminent FDA approval of 3,4-methylenedioxymethamphetamine (MDMA) for posttraumatic stress disorder (PTSD) expected in 2024 and psilocybin for major depressive disorder (MDD) likely in 2025. Psychedelics are unique medications in many ways, but especially due to the mental...

Totes and trauma 3: a schematic for trauma persistence

Kybernetes September 21, 2023 Kip Errett Patterson

Purpose The purpose of this conceptual paper is to demonstrate how memes perpetuate trauma with a schematic. This conceptual paper uses the “begin with the end in mind” meme to format the presentation of the necessary components for the schematic of how trauma persists across generations. It is the third paper in a series of applications of the recursive, test-operate-test schematic to the...

Revisión sobre estudios del uso de microdosificación con alucinógenos que combinan técnicas psicoterapéuticas con administraciones de LSD, MDMA o Psilocibina, como complementos farmacológicos en psicopatologías crónicas, trastornos moderados, altos, graves o crónicos, así como en enfermedades potencialmente mortales

September 1, 2023 Aldo Chiquini

La microdosificación (o las microdosis) hace referencia al ingerir una dosis muy baja de una sustancia psicodélica, donde no hay efectos de alteraciones cognitivas, afectivas, perceptivas y neurofisiológicas. Recientemente instituciones como la MAPS, la Universidad Johns Hopkins, el Imperial College of London y la FDA, a dicha microdosificación le han designado como «terapia innovadora», ya que...